ASX:CUVBiotechs
Assessing Clinuvel Pharmaceuticals (ASX:CUV) Valuation After EMA SCENESSE Approval And Half Year Earnings
Clinuvel Pharmaceuticals (ASX:CUV) is in focus after a key European Medicines Agency approval for year round SCENESSE use in erythropoietic protoporphyria, alongside fresh half year earnings that show revenue of A$40.56 million and net income of A$10.44 million.
See our latest analysis for Clinuvel Pharmaceuticals.
Even with the EMA approval and fresh half year numbers, sentiment around Clinuvel looks cautious. A 1 day share price return of 9.33% decline and a year to date share price return...